Summary & Overview
HCPCS C9457: Sulfur Hexafluoride Lipid Microsphere Injection, per mL
HCPCS Level II code C9457 denotes an injection of sulfur hexafluoride lipid microsphere charged per milliliter, used as an ultrasound contrast agent to improve visualization during diagnostic sonography. Nationally, contrast agents coded separately are important for accurate facility and professional billing, influence imaging workflow costs, and affect payer coverage policies for advanced ultrasound studies.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise presentation of payer coverage patterns and common billing considerations, where available, along with clinical context explaining typical use in ultrasound-enhanced imaging. The piece also outlines what to expect in benchmark reporting and policy updates relevant to contrast agent coding.
This analysis helps administrators, billers, and policy analysts understand how C9457 fits into diagnostic imaging service lines, where it is typically administered, and why separate coding for contrast agents matters for reimbursement and clinical documentation. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code C9457 describes an injection preparation of sulfur hexafluoride lipid microsphere, billed per milliliter. This product is an ultrasound contrast agent administered by injection to enhance sonographic imaging.
Service Type: Contrast agent administration for diagnostic imaging
Typical Site of Service: Hospital outpatient departments, imaging centers, and clinics where diagnostic ultrasound is performed
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult undergoing contrast-enhanced ultrasound (CEUS) for focal liver lesion evaluation. The patient presents to an outpatient radiology or hepatology clinic with abnormal findings on prior CT or MRI or with new hepatic lesion detected on screening ultrasound. The ordering provider schedules a CEUS exam using C9457 (injection, sulfur hexafluoride lipid microsphere, per ml) as the ultrasound contrast agent.
During the clinical workflow, the patient is registered and screened for contrast contraindications (e.g., known hypersensitivity to sulfur hexafluoride or active right-to-left cardiac shunt per facility policy). An intravenous access is established, baseline vital signs are recorded, and informed consent for contrast-enhanced ultrasound is obtained. The sonographer or radiologist prepares the ultrasound unit, draws the appropriate volume of C9457 per the manufacturer dosing and institutional protocol, and performs real-time contrast administration during targeted ultrasound imaging of the liver lesion. Dynamic imaging captures arterial, portal venous, and late phases as indicated. The radiologist interprets enhancement patterns to characterize the lesion (benign vs. malignant), documents the volume and lot number of C9457 used, and records any immediate adverse reactions. The patient is observed briefly post-injection for safety and then discharged with follow-up recommendations documented in the radiology report.
Coding Specifications
| Modifier | Description | When to Use |
|---|